Evidence map›Paper›PMID 26385367›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2016

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC.

Carole Siani, Christian de Peretti, Aurélie Millier, Laurent Boyer, Mondher Toumi

Abstract readMulticenter Study
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy.The European journal of health economics : HEPAC : health economics in prevention and care · 2023
    Article
  3. Article
  4. Article
  5. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carole SianiResearch Laboratory in Knowledge Engineering (ERIC, EA3083), Institute of Pharmaceutical and Biological Sciences (ISPB), University Claude Bernard Lyon 1, 11 Rue Guillaume Paradin, 69372, Lyon Cedex 08, France. carole.siani@univ-lyon1.fr.
Christian de PerettiLaboratory of Actuarial and Financial Sciences (SAF, EA2429), Institute of Financial and Insurance Sciences (ISFA School), University Claude Bernard Lyon 1, 50 Avenue Tony Garnier, 69366, Lyon Cedex 7, France.
Aurélie MillierCreativ-Ceutical, 215 Rue du Faubourg Saint Honoré, 75008, Paris, France. ami@creativ-ceutical.com.
Laurent BoyerLaboratory of Public Health (EA 3279), Faculty of Medicine, Aix-Marseille University, 27 bd Jean Moulin, 13385, Marseille Cedex 05, France.
Mondher ToumiAix-Marseille University, 27 bd Jean Moulin, 13385, Marseille Cedex 05, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe clinical symptoms of schizophrenia are associated with serious social, quality of life and functioning alterations. Typically, data on health utilities are not available in clinical studies in schizophrenia. This makes the economic evaluation of schizophrenia treatments challenging. The purpose of this article was to provide a mapping function to predict unobserved utility values in patients with schizophrenia from the available clinical and socio-demographic information.

methodsThe analysis was performed using data from EuroSC, a 2-year, multi-centre, cohort study conducted in France (N = 288), Germany (N = 618), and the UK (N = 302), totalling 1208 patients. Utility was calculated based on the EQ-5D questionnaire. The relationships between the utility values and the patients' socio-demographic and clinical characteristics (Positive and Negative Syndrome Scale--PANSS, Calgary Depression Scale for Schizophrenia--CDSS, Global Assessment of Functioning--GAF, extra-pyramidal symptoms measured by Barnes Akathisia Scale-BAS, age, sex, country, antipsychotic type) were modelled using a random and a fixed individual effects panel linear model.

resultsThe analysis demonstrated the prediction ability of the used parameters for estimating utility measures in patients with schizophrenia. Although there are small variations between countries, the same variables appear to be the key predictors. From a clinical perspective, age, gender, psychopathology, and depression were the most important predictors associated with the EQ-5D.

conclusionThis paper proposed a reliable, robust and easy-to-apply mapping method to estimate EQ-5D utilities based on demographic and clinical measures in schizophrenia.

Indexed as

Models, TheoreticalSurveys and QuestionnairesAdolescentAdultAgedAntipsychotic AgentsCohort StudiesDepressionDepressive DisorderFemaleFranceGermanyHumansLinear ModelsMaleMiddle AgedAntipsychotic AgentsMappingPositive and Negative Syndrome ScaleQuality of lifeSchizophrenia

Identifiers

PMID26385367
PMCPMC4830865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.